| Backgrounds and ObjectivesNowadays the role of preoperative chemotherapy for gastric carcinoma remains undefined. This study was performed to evaluate the survival benefit that preoperative chemotherapy brings about for patients with locally advanced gastric carcinoma (LAGC).MethodsA single-institution, retrospective evaluation of 180 patients with gastric carcinoma was performed which includes preoperative chemotherapy group (NAC group, n=90) and surgery group (S group, n=90). A survival analysis was conducted for these two groups. We also evaluated the prognostic significance of various clinical and pathological parameters of the NAC group.ResultsThe overall survival (OS) of NAC group was better than the S group’s, but the difference between the two groups had no statistical significance (P=0.096). The univariate and multivariate prognostic analysis of NAC group were performed. Four parameters were identified as the independent prognostic factors:the Borrmann type (P=0.013), RO resection or not (P=0.003), clinical response (P=0.042) and ypN stage (P=0.001).ConclusionsThis study demonstrated the non-inferiority of preoperative chemotherapy which can improve the RO resection rate and be safely delivered in clinical practice. Among the four independent prognostic factors we identified, only the Borrmann type can be got before treatment. We need more RCTs to clarify the role of preoperative chemotherapy in the treatment of LAGC. |
PDF Full Text Request